Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS): valor razonable

Tesis ACCE

Fresenius Medical Care runs dialysis clinics and sells the dialysis machines, filters and consumables those clinics use, making it one of the largest kidney care providers in the world. Its structural edge is scale: the installed base of treatment centres and a recurring stream of consumables give it density that smaller competitors cannot easily match, and dialysis demand is inelastic because patients need treatment several times a week. Revenue growth is only 1.4%, so the case rests on margin and cash conversion rather than top-line expansion; operating margin of 10.8% and a 26.4% gross margin are the numbers to test against peers. At 11.4 times trailing earnings and 8.6 times forward, the stock screens cheap relative to its own history and to the broader healthcare services group, but a 8.5% return on equity and a score of 53 out of 100 say the market has reasons for the discount. The deeper look should focus on whether margin can hold as reimbursement pressure and the mix shift toward home and peritoneal dialysis play out.